Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6

뉴스 본문을 불러오고 있어요.

Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6 | 웨이프 WAPE

Tonix Pharmaceuticals Enrolled First Patient In Phase 2 HORIZON Study Of TNX-102 SL For MDD; Primary Endpoint Is Change In MADRS Total Score At Week 6

기사 요약

관련 종목

댓글 —